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A B S T R A C T
We report on 499 patients with severe aplastic anemia aged  50 years who underwent hematopoietic cell transplan-
tation (HCT) from HLA-matched sibling (n = 275, 55%) or HLA-matched (8/8) unrelated donors (n = 187, 37%) between
2005 and 2016. The median age at HCT was 57.8 years; 16% of patients were 65 to 77 years old. Multivariable analysis
confirmed higher mortality risks for patients with performance score less than 90% (hazard ratio [HR], 1.41; 95% confi-
dence interval [CI], 1.03 to 1.92; P = .03) and after unrelated donor transplantation (HR, 1.47; 95% CI, 1 to 2.16; P = .05).
The 3-year probabilities of survival for patients with performance scores of 90 to 100 and less than 90 after HLA-
matched sibling transplant were 66% (range, 57% to 75%) and 57% (range, 47% to 76%), respectively. The corresponding
probabilities after HLA-matched unrelated donor transplantation were 57% (range, 48% to 67%) and 48% (range, 36% to
59%). Age at transplantation was not associated with survival, but grades II to IV acute graft-versus-host disease
(GVHD) risks were higher for patients aged 65 years or older (subdistribution HR [sHR], 1.7; 95% confidence interval,
1.07 to 2.72; P = .026). Chronic GVHD was lower with the GVHD prophylaxis regimens calcineurin inhibitor
(CNI) +methotrexate (sHR, .52; 95% CI, .33 to .81; P = .004) and CNI alone or with other agents (sHR, .27; 95% CI, .14 to
.53; P < .001) compared with CNI +mycophenolate. Although donor availability is modifiable only to a limited extent,
choice of GVHD prophylaxis and selection of patients with good performance scores are key for improved outcomes.
© 2018 American Society for Blood andMarrow Transplantation. Published by Elsevier Inc. All rights reserved.
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INTRODUCTION
Treatment algorithms for severe aplastic anemia (SAA) are
not well characterized for older patients. For older patients
treatment decisions are based not only on disease factors but
also on their health and functional ability to reduce the risk of
treatment-related toxicity that may contribute to morbidity
and mortality [1]. For these reasons hematopoietic cell trans-
plantation (HCT) in older patients with SAA is usually only con-
sidered as second-line treatment [2].
Existing data on outcomes after HCT or immunosuppressive
therapy (IST) have examined different age groups, >40 years
for HCT [3,4] and >60 years for IST [5-7]. First-line IST using
horse antithymocyte globulin (ATG) and cyclosporine in
patients aged > 60 years is associated with a similar response
as that in younger patients, but survival is worse in older
patients [5,7,8]. Although HLA-matched related and unrelated
donor transplantations are offered to patients who are fit and
as first-line treatment for matched related or those who fail
first-line IST for matched unrelated donor HCT, increasing age
at transplantation (>40 years) remains a concern [4-6]. How-
ever, a recent report on 115 adults failed to show a difference
in survival after HLA-matched sibling transplantation [9]. A
second course of IST is effective in only a third of cases and
increases the risk of later progression to myelodysplastic syn-
drome/acute myeloid leukemia (MDS/AML) [10,11]. The recent
use of eltrombopag for refractory SAA is effective in 40% of
patients, although 19% of patients reported early onset of
abnormal cytogenetic clones (most commonly monosomy 7)
[12].
A retrospective natural history study of aplastic anemia
covering the whole of Sweden has highlighted the significantly
worse survival for patients aged  60 years compared with
younger patients where less than 40% were alive after 5 years
and with a relative 5-year survival (excess mortality) of 45%
[13]. Hence, there is an unmet need to improve the manage-
ment of this older group of patients with aplastic anemia.
However, no data specifically address HCT outcomes in a rela-
tively large cohort of SAA patients older than 50 years. Herein
we report for the first time a cohort of 499 SAA patients older
than 50 years at transplantation and reported to the European
Society for Blood and Marrow Transplant (EBMT) or the Center
for International Blood and Marrow Transplant Research
(CIBMTR).
METHODS
Patients
Data on patients were obtained from 2 international transplant registries,
the CIBTMR and the EBMT. Both registries collect data on consecutive trans-
plantations performed at participating sites, and patients are followed longi-
tudinally until death or loss to follow-up. Transplantations occurred between
2005 and 2016 in Europe or North America. Ethical approval for studying
transplantations reported to the EBMT was granted by the EBMT SAA Work-
ing Party. The Institutional Review Board of the National Marrow Donor Pro-
gram approved studying transplantations reported to the CIBMTR and this
study.
Inclusion Criteria
Eligible patients were aged 50 years or older with SAA and transplanted
from an HLA-matched sibling or adult matched unrelated donor (8/8 reported
or 8/8 high resolution). Patients transplanted from a haploidentical donor,
umbilical cord blood, or who reported a prior HCT were excluded.
Endpoints
Primary endpoint was overall survival. Death from any cause was consid-
ered an event, and surviving patients were censored at 36 months, based on
the median follow-up for this study: 42 months (range, 37 to 49). Neutrophil
engraftment was defined as achieving an absolute neutrophil count
 .5£ 109/L for 2 consecutive days, before day 28. Platelet recovery was
defined as achieving an unsupported platelet count of 20£ 109/L for 7 days,
before day 100. Engraftment failure included primary and secondary graft
failure captured through day 100 and defined as failing to achieve absolute
neutrophil count  .5£ 109/L, donor chimerism < 5%, subsequent loss of
absolute neutrophil count to <.5£ 109/L, or second infusion. Grades II to IV
acute and chronic graft-versus-host disease (GVHD) was defined according to
standard criteria [14,15].
Statistical Analysis
The probability of overall survival was calculated using the Kaplan-Meier
product limit estimation method, and differences in subgroups were assessed
by the log-rank test. All estimates of overall survival are provided at 36
months post-transplant and are reported with corresponding 95% confidence
intervals (CIs). Median follow-up was determined using the reverse Kaplan-
Meier method. Cox proportional hazards regression was used to assess the
impact of potential risk factors on mortality in multivariable analyses, provid-
ing hazard ratios (HRs) with their 95% CIs. The incidences of hematopoietic
recovery, acute and chronic GVHD, and primary and secondary graft failure
were calculated in a competing risk framework. Competing events for each
outcome were mortality, no engraftment, relapse, and second transplant.
Subgroup differences were assessed by Gray's test. Multivariable Fine and
Gray regression was used to study risk factors associated with acute and
chronic GVHD, providing subdistribution HRs (sHR) with 95% CIs. All P values
were w-sided, and P  .05 was considered significant. All analyses were per-
formed in SPSS 23 (Armonk, NY, USA) and in R 3.3.2 (R Development Core
Team, Vienna, Austria) using packages “survival,” “prodlim,” and “cmprsk.”
RESULTS
Patient and Transplant Characteristics
Patient and transplant characteristics are summarized in
Table 1. Comparison of patient characteristics and outcomes
between EBMT and CIBMTR registries are summarized in the
Supplementary Material. The median age at transplantation
was 57.8 years (range, 50 to 77.7). Of 499 patients, most
(n = 420; 84%) were aged 50 to 64 years and only 16% (n = 79)
were 65 years or older. Fifteen patients were 70 years or older,
accounting for only 3% of the patient population.
Karnofsky performance scores of 90 or 100 were observed
in 49% of patients. Sixty-seven percent of patients were cyto-
megalovirus seropositive, and 38.5% of transplantations
(median, 10; range, <1 to 357) occurred at least a year after
diagnosis. Of the patients with available IST information, 89.6%
received at least 1 course of prior immune suppressive treat-
ment. Fifty-five percent of patients received their graft from an
HLA-matched sibling and 38% from an HLA-matched unrelated
donor. For the remaining 7% the degree of mismatching was
unknown. Approximately equal numbers of patients received
bone marrow (53%) and peripheral blood (47%) grafts.
Cyclophosphamide with ATG alone or with ATG and fludar-
abine were the predominant conditioning regimens for
HLA-matched sibling HCT, whereas for unrelated donor HCT
cyclophosphamide with total body irradiation 200 cGy and
ATG or with the inclusion of fludarabine were mostly used.
Most patients received calcineurin inhibitor (CNI)-containing
GVHD prophylaxis. Among the 117 patients who received
CNI +mycophenolate mofetil (MMF), 53 (45%) received an
ATG-containing and 5 (4%) received an alemtuzumab-contain-
ing conditioning regimen. Similarly, 101 of 246 patients (41%)
who received CNI +methotrexate (MTX) received ATG-con-
taining and 7 (3%), alemtuzumab-containing conditioning regi-
mens. Forty-seven of 110 patients (43%) who received CNI
alone or other agents for GVHD prophylaxis received an alem-
tuzumab-containing and 33 of 110 (30%) received an ATG-con-
ditioning regimen.
Because unrelated donor transplants were more recent, the
median follow-up was 38 months (range, 36 to 45) and that
after HLA-matched sibling transplants, 49 months (range, 38
to 58). The median follow-up of the combined population was
42 months (range, 37 to 49), and outcomes were censored at
36 months to accommodate differential follow-up.
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Hematologic Recovery
The incidence of primary graft failure at 100 days was 10%
(range, 7-12%). The incidence of secondary graft failure at 36
months after transplantation among patients with initial
engraftment was 7% (range, 4% to 10%). Day 28 cumulative
incidence of neutrophil recovery was 82% (range, 79% to 86%).
Multivariable analysis for risk factors associated with neutro-
phil recovery is shown in Table 2. Neutrophil recovery was
higher in patients receiving peripheral blood grafts compared
with bone marrow (sHR, 1.74; 95% CI, 1.38 to 2.2; P < .001)
and lower in patients receiving CNI +MTX compared with
CNI +MMF as GVHD prophylaxis (sHR, .59; 95% CI, .44 to .8;
P < .001).
Overall Survival
The 3-year probability of overall survival for the entire
cohort was 56% (range, 52% to 61%) and was 59% (range, 53% to
66%) and 52% (range, 45% to 60%) for matched related and
matched unrelated donor HCT, respectively. The 3-year proba-
bilities of survival for patients with performance scores of 90
to 100 and <90 after HLA-matched sibling transplant were
66% (range, 57% to 75%) and 57% (range, 47% to 76%), respec-
tively (Figure 1). The corresponding probabilities after unre-
lated donor transplantation were 57% (range, 48% to 67%) and
48% (range, 36% to 59%) (Figure 1). None of the other variables
tested, including age at HCT, cytomegalovirus serostatus, graft
type, interval between diagnosis and HCT, and transplant
period, attained the level of significance set for this study.
Multivariable analysis confirmed higher mortality risks for
patients with a performance score of less than 90% and recipi-
ents of unrelated donor HCT (Table 2). The effects of perfor-
mance score and donor type on overall survival were
independent of each other.
There was no significant difference in mortality risk for
older patients aged 65 to 78 years compared with those aged
50 to 64 years (HR, 1.20; 95% CI, .81 to 1.81; P = .343). There
were 215 deaths; infection was the predominant cause of
death, accounting for 40% of deaths followed by GVHD (13%),
multiorgan failure (10%), and graft failure (9%). Other causes
included malignancy, including Epstein-Barr virus associated
post-transplant lymphoproliferative disease (5%), interstitial
pneumonitis (1%), and other toxicities (7%). The cause of death
was not reported for 15% of patients.
Graft-versus-Host Disease
The day 100 incidence of acute GVHD in patients aged 50 to
64 years was 20% (range, 16% to 24%) and those aged 65 years
and older, 35% (range, 24% to 46%; P = .006) (Figure 2A; see
Figure 2B for chronic GVHD). The corresponding incidence for
patients who received CNI +MMF was 33% (range, 24% to 42%),
CNI +MTX 24% (18% to 29%), and CNI alone or other GVHD pro-
phylaxis regimens 13% (range, 7% to 20%), respectively
Table 1
Patient Characteristics
Characteristic Subcategory No. of Cases or Median Percent or Range
Registry CIBMTR 194 38.9
EBMT 305 61.1
Age 65 yr 79 15.8
50-64 yr 420 84.2
Patient sex Female 245 49.1
Male 254 50.9
Performance score <90% 190 38.1
90-100% 243 48.7
Missing 66 13.2
Patient cytomegalovirus Negative 126 25.3
Positive 335 67.1
Missing 38 7.6
Interval from diagnosis to treatment 12 yr 307 61.5
>12 yr 192 38.5
Donor Matched unrelated 187 37.5
HLA-identical sibling 275 55.1
Missing 37 7.4
Graft source Bone marrow 266 53.3
Peripheral blood 233 46.7
Regimen Cy + ATG 91 18.2
Cy + Flud § ATG 92 18.4
TBI 200 + Cy + Flud + ATG 57 11.4
TBI 200 + Cy § ATG 28 5.6
Alkylating agent + Flud § ATG 65 13
Alemtuzumab 60 12
Flud + Cy + alemtuzumab 40
Alemtuzumab + other 20
Other non-TBI regimen 73 14.6
Other TBI regimens 18 3.6
Missing 15 3
GVHD prophylaxis CNI +MMF 117 23.4
CNI +MTX 246 49.3
CNI § other drug 67 13.4
Other 43 8.6
Missing 26 5.2
HSCT year 2005-2009 191 38.3
2010-2014 308 61.7
Age, yr Median (range) 499 57.8 (50-77.7)
Interval from diagnosis to treatment, yr Median (range) 499 .8 (<1-29.7)
Follow-up Median (95% CI) 42.4 (37.2-48.9)
Cy indicates cyclophosphamide; Flud, fludarabine; TBI, total body irradiation.
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(Figure 2C). The results of multivariable analysis for risk factors
associated with acute and chronic GVHD are shown in Table 3.
Risk for grades II to IV acute GVHD was higher for patients
aged 65 years and older and lower for those who received CNI
alone or other agents compared with CNI +MMF (sHR, .48; 95%
CI, .26 to .88; P = .018).
The 3-year incidences of chronic GVHD were 49% (range,
39% to 59%) with CNI +MMF, 31% (range, 24% to 38%) with
CNI +MTX, and 18% (range, 9% to 26%) with CNI alone or other
GVHD prophylaxis (P < .001) (Figure 2D). The only risk factor
associated with chronic GVHD was GVHD prophylaxis regi-
men. Risks were lower with CNI +MTX (sHR, .52; 95% CI, .33 to
.81; P = .004) and CNI alone or with other agents (HR, .27; 95%
CI, .14 to .53; P < .001) compared with CNI +MMF.
DISCUSSION
Reported here is the first global study evaluating outcomes
after matched related and matched unrelated donor HCT for
SAA patients aged  50 years including 79 patients who were
aged between 65 and 77 years. Patients undergoing second
transplant were excluded from this study, making the data
more specific and providing more accurate interpretation of
graft failure, especially late graft failure. The current analyses
support allogeneic transplantation as an acceptable treatment
option for older adults who fail IST with careful attention to
patient selection. The upper age limit for upfront matched
related HCT has been steadily rising over time as outcomes
continue to improve. A cutoff at 35 to 50 years has been recom-
mended, depending on patient comorbidities [2], although
recently for patients aged 41 to 60 years it has been suggested
that upfront transplantation might be carefully considered in
selected patients who are medically fit [6]. Otherwise, first-line
treatment for older patients is IST. In older patients who lack
an HLA-matched related donor, HLA-matched unrelated donor
HCT is only offered after failure to respond to IST.
We have shown that the 3-year survival exceeds 50% after
related and unrelated donor HCT. Although unrelated donor
HCT was independently associated with worse survival, the
availability of a matched sibling is not a modifiable factor. Opti-
mizing patient selection by considering referral after failure of
1 course of IST and initiation of donor search at diagnosis for
those who are “fit” with good performance scores may mitigate
mortality risks. We were not able to assess HCT-specific comor-
bidity index scores because of a lack of available data. We also
examined for any interaction between performance status and
age on clinical outcomes to demonstrate their separate effects
(see Supplementary Material). Both acute and chronic GVHD
were exceptionally low with alemtuzumab-containing condi-
tioning regimens. Although patient numbers are small (60
patients received alemtuzumab-containing regimens), consid-
ering transplant strategies that include alemtuzumab may help
lower the burden of morbidity and perhaps late mortality,
Table 2
Risk Factors for Overall Survival and Neutrophil Recovery
Risk Factor Subcategory No. of Cases No. of Events HR (95% CI) P
Overall survival
Total 424 164
Registry EBMT 246 88
CIBMTR 178 76 .98 (.71-1.36) .918
Age 50-64 yr 354 132
65 yr 70 32 1.21 (.81-1.81) .343
Patient sex Male 216 88
Female 208 76 .82 (.6-1.12) .205
Performance score <90% 189 83
90-100% 235 81 .71 (.52-.97) .03
GVHD prophylaxis CNI +MMF 99 39
CNI +MTX 223 91 1.22 (.82-1.81) .319
Other 102 34 .86 (.54-1.38) .537
Donor Identical sibling 221 78
Unrelated donor 203 86 1.47 (1-2.16) .05
Regimen Non-TBI regimen 321 122
TBI regimen 103 42 .76 (.49-1.19) .226
Graft source Bone marrow 229 90
Peripheral blood 195 74 .96 (.7-1.32) .813
Interval from diagnosis to treatment, yr 424 .99 (.94-1.05) .818
sHR (95% CI)
Neutrophil recovery
Total 406 368
Registry EBMT 232 210
CIBMTR 174 158 1.32 (1.06-1.65) .014
Age 50-64 yr 337 307
65 yr 69 61 .95 (.7-1.3) .76
Performance score <90% 181 158
90-100% 225 210 1.24 (.99-1.54) .062
Patient cytomegalovirus Negative 114 105
Positive 292 263 1.13 (.91-1.41) .27
GVHD prophylaxis CNI +MMF 98 92
CNI +MTX 210 188 .59 (.44-.8) <.001
Other 98 88 .78 (.55-1.1) .15
HSCT period 2005-2009 133 119
2010-2014 273 249 1.14 (.89-1.45) .29
Donor Identical sibling 210 189
Unrelated donor 196 179 .99 (.79-1.24) .92
Graft source Bone marrow 223 199
Peripheral blood 183 169 1.74 (1.38-2.2) <.001
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although mortality within the first 3 years after HCT was not
associated with use of alemtuzumab. The other potential bene-
fits of alemtuzumab instead of ATG are that addition of MTX to
a CNI is not required, thus eliminating the risk of mucositis,
reducing the risk of hepatotoxicity, and avoiding total body
irradiation containing regimens even for unrelated donor HCT.
Additionally, peripheral blood stem cells can be used with
alemtuzumab because of very low GVHD with the added bene-
fit of a higher incidence of engraftment [16,17].
Other studies that have examined the effect of donor type
(younger unrelated donor or older sibling) have limited unre-
lated donor transplant recipients to those who received grafts
from a young unrelated donor [18]. With the additional limita-
tion of the unrelated donor transplant recipients to HLA-
matched transplants, the study population was not adequately
powered to detect differences in survival based on donor age.
The question of 1 versus multiple prior courses of IST was
not addressed in the current analyses, because these data,
along with number of prior transfusions, are not routinely cap-
tured in this registry-based retrospective study. Survival after
IST is age dependent, with worse survival among older patients
compared with younger patients. A retrospective EBMT study
of 242 patients aged > 50 years reported a 5-year survival of
57% for patients aged 50 to 59 years and 50% for 60 years [7].
A subsequent prospective randomized EBMT study of first-line
ATG and cyclosporine with or without granulocyte colony-
stimulating factor showed that for patients aged >60 years the
3- and 6-year overall survival was 65% and 56%, respectively
[19]. In a national study from Sweden, 5-year survival for
patients aged  60 years treated with IST from 2000 to 2011
was 52% [13]. Thus, survival after HLA-matched related HCT is
comparable with that after IST therapy in this older age group.
Other factors to consider with IST in older patients are, for
example, that unlike in a younger population, use of ATG in
older patients is associated with arrhythmia, cardiac failure,
and sudden cardiac ischemic events, all of which adds to the
burden of morbidity and mortality [3]. The next question is
how survival after HLA-matched HCT compares with a second
course of IST with ATG and cyclosporine or other ISTs such as
alemtuzumab. Hematologic response occurs in only 30% to 40%
of patients of all age groups after a second course of IST given
for refractory SAA [10,20]. We are not aware of any published
Figure 1. Factors affecting overall survival. (A) Overall survival by age < 65 versus 65 years. (B) Overall survival by by stem cell source. (C) Overall survival by per-
formance status. (D) Overall survival by by donor type. The shaded regions indicate the corresponding 95% CIs. Reported P values are based on the log-rank test.
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data on response or survival after 2 or more courses of IST
among older patients, although a retrospective EBMT study
found that repeat courses of IST had no significant impact on
survival [7]. Additionally, MDS/AML and solid tumors may
occur in 15% and 11% of patients, respectively, at 10 years after
IST, and multiple courses of ATG increase the risk of developing
MDS/AML [11,21,22].
Others have used cyclosporine as monotherapy, but
response rates are lower than with the addition of ATG [23,24].
The use of eltrombopag for refractory SAA has improved
response rates to 40%, but the early risk of clonal cytogenetic
abnormality is 19% (median time to cytogenetic abnormality
was 3 months), and monosomy 7 was the most common [12].
Taken together, in fit older patients with a suitable HLA-
matched sibling or unrelated donor, transplantation after fail-
ure of 1 course of IST may be an alternative treatment option.
Long-term survival after HCT for SAA is excellent, and the pre-
dominant cause of late mortality was GVHD-associated death,
which in the recent era may be mitigated with alemtuzumab-
containing regimens [17,18].
The incidence of and indication for allogeneic HCT in older
patients with hematologic disorders are increasing worldwide
[25], concurrent with improved clinical outcomes, an increased
risk of hematologic malignancies [26], and a rising aged popu-
lation globally. This is mirrored by a steady increase in the
number of transplants being performed for SAA over the last
decade, especially unrelated donor HCT (Figure 3). The ques-
tion as to whether patient age remains relevant has been
recently debated for hematologic malignancies [27]. Although
we failed to detect a significant difference in survival between
those aged 50 to 64 and 65 years or older, this should be inter-
preted with caution because the latter group accounted for
only 16% of transplantations in the current analyses.
A further consideration for any patient age group is that if
HCT is deferred until after the development of MDS/AML, out-
comes of HCT are inferior [28,29]. Before consideration of HCT
in older patients with SAA and at time of diagnosis, it is impor-
tant to exclude hypocellular MDS, which may frequently
mimic SAA on morphologic grounds [30]. MDS is far more
common than SAA in older patients, with a median age at
Figure 2. Factors affecting GVHD. (A) Acute GVHD incidence by age. (B) Chronic GVHD incidence by age. (C) Acute GVHD incidence by GVHD prophylaxis. (D) Chronic
GVHD incidence by GVHD prophylaxis. The shaded regions indicate the corresponding 95% CIs. Reported P values are based on Gray's test. Of 116 patients who
received CNI + other, 50 (43%) received alemtuzumab-based conditioning.
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onset of MDS of 62 years. A diagnosis of MDS instead of SAA
would impact the choice of conditioning regimen for HCT.
Metaphase cytogenetics may not be discriminating, because
up to 12% of SAA patients have an abnormal cytogenetic clone
at diagnosis [31]. Even the presence of an acquired somatic
mutation that is recurrent for MDS/AML such as ASXL1 or
DNMT3A does not necessarily prove a diagnosis of hypocellu-
lar MDS instead of SAA, because small clones can be found in
some SAA patients [10,32] as well as in normal older individu-
als as part of age-related clonal hematopoiesis [33-35].
We conclude that HCT deserves consideration as an option
in older patients with SAA who have failed first-line IST. Better
survival in patients with good performance score emphasizes
the critical importance of preassessment of patients in terms
of comorbidities. This will aid discussions with the patient
about a potentially curative disease approach rather than dis-
ease-free survival associated with nontransplant options.
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Table 3
Risk Factors for Acute and Chronic GVHD
Risk Factor Subcategory No. of Cases No. of Events sHR (95% CI) P
Acute GVHD
Total 404 95
Registry EBMT 229 36
CIBMTR 175 59 2.39 (1.55-3.67) <.001
Age 50-64 yr 337 71
65 yr 67 24 1.7 (1.07-2.72) .026
Patient sex Male 208 52
Female 196 43 .86 (.56-1.32) .49
Performance score <90% 180 41
90-100% 224 54 1.2 (.78-1.85) .41
GVHD prophylaxis CNI +MMF 96 32
CNI +MTX 210 47 .69 (.43-1.11) .13
Other 98 16 .54 (.29-1.01) .054
Regimen Non-TBI regimen 303 62
TBI regimen 101 33 .96 (.55-1.67) .87
Donor Identical sibling 209 35
Unrelated donor 195 60 2.01 (1.18-3.42) .011
Graft source Bone marrow 220 53
Peripheral blood 184 42 .94 (.62-1.42) .78
Interval from diagnosis to treatment, yr 404 1.06 (1-1.12) .033
Chronic GVHD
Total 315 98
Registry EBMT 143 38
CIBMTR 172 60 1.3 (.85-2.01) .23
Age 50-64 yr 261 77
65 yr 54 21 1.2 (.74-1.97) .46
Patient sex Male 155 54
Female 160 44 .84 (.56-1.26) .4
Performance score <90% 142 42
90-100% 173 56 1.11 (.72-1.7) .64
GvHD prophylaxis CNI +MMF 76 38
CNI +MTX 166 48 .52 (.33-.81) .004
Other 73 12 .27 (.14-.53) <.001
Regimen Non-TBI regimen 229 70
TBI regimen 86 28 .94 (.51-1.75) .85
Donor Identical sibling 158 47
Unrelated donor 157 51 1.11 (.65-1.88) .71
Graft source Bone marrow 179 49
Peripheral blood 136 49 1.31 (.85-2) .22
Interval from diagnosis to treatment, yr 315 1.03 (.96-1.1) .46
Figure 3. Number of transplants performed each year of the study by donor
type: HLA-identical sibling and unrelated donor.
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